Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lessened its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 4.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 231,941 shares of the company's stock after selling 11,502 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.23% of Neurocrine Biosciences worth $26,724,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. GSA Capital Partners LLP lifted its holdings in shares of Neurocrine Biosciences by 441.3% in the 3rd quarter. GSA Capital Partners LLP now owns 8,682 shares of the company's stock worth $1,000,000 after buying an additional 7,078 shares during the period. Los Angeles Capital Management LLC lifted its stake in Neurocrine Biosciences by 639.6% in the third quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company's stock worth $48,479,000 after acquiring an additional 363,863 shares during the period. Crossmark Global Holdings Inc. grew its holdings in Neurocrine Biosciences by 16.5% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 8,487 shares of the company's stock worth $978,000 after acquiring an additional 1,204 shares in the last quarter. Sigma Planning Corp bought a new position in Neurocrine Biosciences during the 3rd quarter worth about $230,000. Finally, Covestor Ltd increased its position in Neurocrine Biosciences by 11.5% during the 3rd quarter. Covestor Ltd now owns 1,779 shares of the company's stock valued at $205,000 after purchasing an additional 183 shares during the period. Hedge funds and other institutional investors own 92.59% of the company's stock.

Neurocrine Biosciences Trading Down 4.4 %

Shares of NBIX stock traded down $5.44 during trading hours on Friday, hitting $117.44. The company's stock had a trading volume of 1,255,345 shares, compared to its average volume of 997,520. The company has a 50 day moving average of $118.50 and a 200 day moving average of $132.63. Neurocrine Biosciences, Inc. has a 12-month low of $107.84 and a 12-month high of $157.98. The stock has a market cap of $11.89 billion, a PE ratio of 31.49 and a beta of 0.35.

Wall Street Analysts Forecast Growth

NBIX has been the topic of a number of recent research reports. HC Wainwright reiterated a "buy" rating and set a $190.00 price objective on shares of Neurocrine Biosciences in a research note on Friday, November 1st. Citigroup increased their target price on Neurocrine Biosciences from $150.00 to $158.00 and gave the company a "neutral" rating in a research report on Friday, August 2nd. Royal Bank of Canada reduced their price target on Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating for the company in a research report on Friday, October 4th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, September 16th. Finally, BMO Capital Markets reduced their target price on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a "market perform" rating for the company in a report on Thursday, October 17th. Five equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.